Showing results (71-80 of 98) with videos related to
Sort By:
Pageof 10
Neurosurgery|March 28, 2022
Spine Stereotactic Body Radiotherapy for Prostate Cancer Metastases and the Impact of Hormone Sensitivity Status on Local ControlAhmed Abugharib, K Liang Zeng, Chia-Lin Tseng, et al.Current Opinion in Supportive and Palliative Care|January 29, 2026
Comparison of the EORTC QLQ PR25 and the FACT-P for assessing quality of life in patients with prostate cancer - an updated literature reviewDavid Chen, Jane Jomy, Tony Ning, et al.Journal of Geriatric Oncology|February 13, 2024
Understanding the incidence, duration, and severity of symptoms through daily symptom monitoring among frail and non-frail older patients receiving metastatic prostate cancer treatmentsMilothy Parthipan, Gregory Feng, Henriette Breunis, et al.Cancer Research|September 18, 2004
Increased plasma vascular endothelial growth factor (VEGF) as a surrogate marker for optimal therapeutic dosing of VEGF receptor-2 monoclonal antibodiesGuido Bocci, Shan Man, Shane K Green, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 23, 2009
Phase I/II trial of metronomic chemotherapy with daily dalteparin and cyclophosphamide, twice-weekly methotrexate, and daily prednisone as therapy for metastatic breast cancer using vascular endothelial growth factor and soluble vascular endothelial growth factor receptor levels as markers of responseNan Soon Wong, Robert A Buckman, Mark Clemons, et al.Journal of Geriatric Oncology|March 29, 2023
Symptom experiences of older adults during treatment for metastatic prostate cancer: A qualitative investigationMilothy Parthipan, Gregory Feng, Nelly Toledano, et al.Journal of Geriatric Oncology|March 14, 2023
Feasibility and acceptability of remote symptom monitoring (RSM) in older adults during treatment for metastatic prostate cancerGregory Feng, Milothy Parthipan, Henriette Breunis, et al.The Prostate|February 17, 2015
Safety of enzalutamide in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel: expanded access in North AmericaAnthony M Joshua, Neal D Shore, Fred Saad, et al.European Urology Oncology|November 18, 2025
Patient-reported Outcomes for Men with Metastatic Castration-resistant Prostate Cancer Who Received Olaparib plus Abiraterone Versus Placebo plus Abiraterone in the Phase 3 PROpel StudyAndrew J Armstrong, Fred Saad, Mototsugu Oya, et al.Cancer Management and Research|December 6, 2019
Population-Based Analysis Of The Use Of Radium-223 For Bone-Metastatic Castration-Resistant Prostate Cancer In Ontario, And Of Factors Associated With Treatment Completion And OutcomeSierra Cheng, Vanessa Arciero, Hanan Goldberg, et al.Pageof 10